Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masaaki Inoue

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
Clinical Lung Cancer|August 11, 2016
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403Naohiro Oda, Eiki Ichihara, Katsuyuki Hotta, et al.
International Journal of Cancer|January 10, 2024
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancerAyako Morita, Eiki Ichihara, Koji Inoue, et al.
Clinical Lung Cancer|July 14, 2016
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405)Hideko Isozaki, Katsuyuki Hotta, Eiki Ichihara, et al.
Lung Cancer (Amsterdam, Netherlands)|October 23, 2020
Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysisKadoaki Ohashi, Kiichiro Ninomiya, Hiroshige Yoshioka, et al.
Journal of Cancer Research and Clinical Oncology|February 12, 2024
Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry studyTadahiro Kuribayashi, Kadoaki Ohashi, Kazuya Nishii, et al.
Thoracic Cancer|January 12, 2021
Novel prospective umbrella-type lung cancer registry study for clarifying clinical practice patterns: CS-Lung-003 study protocolKazuya Nishii, Masaaki Inoue, Hideto Obata, et al.
Plos One|May 19, 2023
Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201Hiromasa Yamamoto, Junichi Soh, Norihito Okumura, et al.
BMC Cancer|October 21, 2016
A diagnostic marker for superficial urothelial bladder carcinoma: lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progressionMakoto Kawaguchi, Noboru Hara, Vladimir Bilim, et al.
Molecular and Clinical Oncology|July 22, 2025
Association of the expression of 5-FU biomarkers with aging and prognosis in elderly patients with lung cancer treated with S-1 adjuvant chemotherapy: Follow-up results of the Setouchi Lung Cancer Group Study 1201Junichi Soh, Hiromasa Yamamoto, Norihito Okumura, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Clinical Lung Cancer|August 11, 2016
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403Naohiro Oda, Eiki Ichihara, Katsuyuki Hotta, et al.
International Journal of Cancer|January 10, 2024
Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancerAyako Morita, Eiki Ichihara, Koji Inoue, et al.
Clinical Lung Cancer|July 14, 2016
Protocol Design for the Bench to Bed Trial in Alectinib-Refractory Non-Small-Cell Lung Cancer Patients Harboring the EML4-ALK Fusion Gene (ALRIGHT/OLCSG1405)Hideko Isozaki, Katsuyuki Hotta, Eiki Ichihara, et al.
Lung Cancer (Amsterdam, Netherlands)|October 23, 2020
Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysisKadoaki Ohashi, Kiichiro Ninomiya, Hiroshige Yoshioka, et al.
Journal of Cancer Research and Clinical Oncology|February 12, 2024
Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry studyTadahiro Kuribayashi, Kadoaki Ohashi, Kazuya Nishii, et al.
Thoracic Cancer|January 12, 2021
Novel prospective umbrella-type lung cancer registry study for clarifying clinical practice patterns: CS-Lung-003 study protocolKazuya Nishii, Masaaki Inoue, Hideto Obata, et al.
Plos One|May 19, 2023
Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201Hiromasa Yamamoto, Junichi Soh, Norihito Okumura, et al.
BMC Cancer|October 21, 2016
A diagnostic marker for superficial urothelial bladder carcinoma: lack of nuclear ATBF1 (ZFHX3) by immunohistochemistry suggests malignant progressionMakoto Kawaguchi, Noboru Hara, Vladimir Bilim, et al.
Molecular and Clinical Oncology|July 22, 2025
Association of the expression of 5-FU biomarkers with aging and prognosis in elderly patients with lung cancer treated with S-1 adjuvant chemotherapy: Follow-up results of the Setouchi Lung Cancer Group Study 1201Junichi Soh, Hiromasa Yamamoto, Norihito Okumura, et al.
Pageof 6